A study published in Nature Microbiology demonstrates that a defined consortium of 15 gut bacterial species derived from immunotherapy responders significantly enhances anti-PD-1 treatment efficacy in mouse models of non-small-cell lung cancer.
Researchers at Stony Brook University developed an oral vaccine using modified Listeria monocytogenes that generates anti-tumor immune responses in the gut and significantly improves colorectal cancer control when combined with checkpoint inhibitors.
CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.